<DOC>
	<DOCNO>NCT02087332</DOCNO>
	<brief_summary>Study hypothesis time randomization increase natriuresis ( % ) , time standardization natriuresis daily profile , blood pressure profile percentage reduction central hemodynamic parameter relatively change study period 15 % .</brief_summary>
	<brief_title>Investigator Initiated Randomized Open-label Comparative Study Britomar ( Prolonged Release Torasemide ) Diuver ( Torasemide ) Assess Effects Natriuresis Central Hemodynamics .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<criteria>1 . Men woman age 40 70 year . 2 . Established diagnosis IIIII grade essential arterial hypertension 3 . NYHA IIIII chronic heart failure 4 . Saltsensitivity 5 . Stable therapy 3 month prior enrollment study include diuretic , ACEinhibitor , betablocker . 6 . Signed informed consent participation study . 7 . Women childbearing potential agree use effective birth control method screen completion study , exclude situation sexual partner ( ) surgically sterilize , wh–µn woman sexual contact . Effective method birth control contraception method use constantly regularly ( include implantable contraceptive , injectable contraceptive , oral contraceptive , transdermal contraceptive , intrauterine device , diaphragm spermicide , male female condom cervical cap ) . 1 . Unlikely cooperation patient study period , disability 2 . Identification salt resistance screen 3 . Patients myocardial infarction , unstable angina pectoris , percutaneous coronary intervention heart failure , hypertensive encephalopathy , cerebrovascular accident ( stroke ) transient ischaemic attack last 3 month . 4 . Patients severe heart failure ( Stage IV New York Heart Association ) , clinically significant aortic valve mitral stenosis , uncorrected coarctation aorta , obstruction cardiac output ( obstructive hypertrophic cardiomyopathy ) 5 . Previous glomerulonephritis , severe pyelonephritis another know severe renal disease confirm GFR &lt; 40 ml/min/1.73 m2 calculate CockroftGault formula . 6 . Secondary arterial hypertension , severe uncontrolled AH study enrollment ( BP &gt; 180 mm Hg DAP &gt; 110 mm Hg ) 7 . Any severe , decompensated unstable disease condition , investigator 's opinion , endanger patient 's life aggravate disease prognosis ( decompensated heart failure , anemia , severe diabetes mellitus , autoimmune , oncological disease , hepatic , allergic reaction , connective tissue disease , etc . ) 8 . Acute infectious disease . 9 . Hypersensitivity component Britomar Diuver 10 . Pregnancy , lactation period . 11 . Participation another clinical study last 30 day . 12 . Scheduled coronary artery surgery ( example , stent implantation coronary artery bypass graft ) noncardiological major surgery . 13 . 13 . Administration drug affect natriuresis level ( diuretic relate study product ) . Patients exclude study take drug last 48 year Visit D 10 , screen period and/or treatment period/followup period study . 14 . Use narcotic drug alcohol abuse last 6 month inability/unwillingness refrain narcotic drug excessive alcohol intake study period . The excessive alcohol intake average alcohol &gt; 2 unit alcohol . A unit alcohol various beverage 12 ounce ( 350 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 % alcohol . 15 . Any reason would hinder patient ' compliance study requirement understand study aim potential risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Kidney damage hypertension cardiovascular disease , congestive heart failure renal function natriuresis natriuresis monitoring</keyword>
</DOC>